Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01564914 · ClinicalTrials.gov registry record · Phase 2

A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma

A Phase 2 study of Glioblastoma and Glioblastoma Multiforme, sponsored by Tracon Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
22
Enrollment target
4
Study locations

NCT01564914 is a Phase 2 study of Glioblastoma and Glioblastoma Multiforme that has completed, run by Tracon Pharmaceuticals. The registered enrollment target is 22 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (80% lower). The trial reports 4 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01564914, a Phase 2 study of Glioblastoma and Glioblastoma Multiforme, has completed, sponsored by Tracon Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
22 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent or progressive glioblastoma after prior antiangiogenic therapy (including anti-VEGF therapy)

Conditions Studied

Glioblastoma Glioblastoma Multiforme

Interventions

  • DRUG Bevacizumab
  • DRUG TRC105

Study Locations (4)

Ohio

  • University of Cincinnati - Cincinnati
  • University Hospitals of Cleveland - Cleveland
  • Cleveland Clinic - Cleveland
  • Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2012-05
Est. Completion 2015-06
Phase Phase 2

Sponsor

Tracon Pharmaceuticals

16 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01564914

The ClinicalTrials.gov registry entry for NCT01564914 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (80% lower). The listed sponsor is Tracon Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.

NCT01564914 reports 4 study locations spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT01564914 about?

NCT01564914 is a clinical study titled "A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma". The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent or progressive glioblastoma after prior antiangiogenic therapy (including anti-VEGF therapy)

What is the current status of trial NCT01564914?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2012-05. Estimated completion is 2015-06.

What conditions does trial NCT01564914 study?

This clinical trial studies the following conditions: Glioblastoma, Glioblastoma Multiforme.

What interventions are being tested in trial NCT01564914?

The interventions under investigation include: Bevacizumab (DRUG), TRC105 (DRUG).

Who is sponsoring clinical trial NCT01564914?

This trial is sponsored by Tracon Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01564914 being conducted?

This trial has 4 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Glioblastoma

All registered trials for this condition

Glioblastoma Multiforme

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.